Rilzabrutinib is a small molecule commercialized by , with a leading Phase III program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). According to Globaldata, it is involved in 25 clinical trials, of which 18 were completed, 4 are ongoing, 2 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Rilzabrutinib鈥檚 valuation in its risk-adjusted NPV model (rNPV). .
The revenue for Rilzabrutinib is expected to reach an annual total of $242 mn by 2034 in the US based off GlobalData鈥檚 Expiry Model. The drug鈥檚 revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug鈥檚 phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Rilzabrutinib Overview
Rilzabrutinib (PRN-1008) is under development for the treatment of autoimmune hemolytic anemia, immune thrombocytopenic purpura, asthma, Chronic spontaneous urticaria, atopic dermatitis, purigo nodularis and IgG4-related disease. The drug candidate is a small molecule administered orally. The drug candidate targets Bruton's tyrosine kinase (BTK) enzyme. It is based on Tailored covalency technology platform. It was also under development for rheumatoid arthritis, systemic lupus erythematosus (SLE) and inflammatory bowel disease.
Rilzabrutinib was under development for the treatment of pemphigus foliaceus, newly diagnosed or relapsing pemphigus vulgaris,
Sanofi Overview
is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women鈥檚 health; and vitamins, minerals, and supplements. ‘s R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Africa, Asia-Pacific, and the Middle East. is headquartered in Paris, Ile-de-France, France.
The company reported revenues of (Euro) EUR46,444 million for the fiscal year ended December 2023 (FY2023), an increase of 2.3% over FY2022. In FY2023, the company鈥檚 operating margin was 17%, compared to an operating margin of 23.5% in FY2022. In FY2023, the company recorded a net margin of 11.6%, compared to a net margin of 18.4% in FY2022.
The company reported revenues of EUR11,118 million for the first quarter ended March 2024, a decrease of 55.3% over the previous quarter.
For a complete picture of Rilzabrutinib鈥檚 valuation,
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData鈥檚 unrivalled proprietary data will enable you to decode what鈥檚 happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
